Trial reportFrontiers in nutrition2026
Effects of gochujang formulations on menopausal symptoms and gut microbiota in postmenopausal women: an 8-week randomized, double-blind trial.
Trial report in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Menopause-associated symptoms impair quality of life, and postmenopausal women increasingly seek safe, non-hormonal, diet-based interventions. Gochujang, a traditional Korean fermented food rich in isoflavone aglycones and capsaicinoids, has biological activities relevant to menopausal health but has never been tested in a randomized trial. We compared three distinct Gochujang formulations. Methods: In this 8-week, randomized, double-blind, three-arm trial, two Gochujang formulations differing in microbial composition (high-microorganism [HTG], low-microorganism [LTG]) were compared with commercial Gochujang (CG) in 59 postmenopausal women with moderate-to-severe symptoms [Kupperman Menopausal Index (KMI) ≥15]. Change in total KMI score and change in gut microbiota were the two registered co-primary outcomes, and change in total KMI score is the primary endpoint of this report. Because all arms received active Gochujang without a placebo, the trial assessed between-formulation differences rather than efficacy. Secondary outcomes were body composition, metabolic biomarkers, and safety; gut microbiota and fecal short-chain fatty acids (SCFAs) are analyzed here as exploratory outcomes, a Results: All formulations produced significant within-group KMI reductions (HTG: -3.65, 95% CI -4.97 to -2.33; LTG: -4.10, -5.98 to -2.22; CG: -3.42, -4.34 to -2.50; all Discussion: Eight-week Gochujang consumption was safe, well-tolerated, and associated with reduced menopausal symptom severity and percent body fat across all formulations. Efficacy cannot be established without a placebo control; placebo-controlled trials with endocrine and functional microbiome endpoints are warranted. Clinical trial registration: https://cris.nih.go.kr, identifier KCT0011085.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.